Markets:

Overview

News

Currencies

International

Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

105.55 -0.69 (-0.65%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

18 19 20 21 22 23 24 25 Next >

Stock Market Rally Under Pressure As Walmart, Target Crash On Inflation Woes: Weekly Review ↗

May 20, 2022

A confirmed market uptrend is reeling as inflation's pain bites.

Via Investor's Business Daily

Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted ↗

May 13, 2022

Via Benzinga

Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas ↗

May 13, 2022

Key takeaways: Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule The...

Via Benzinga

Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now ↗

May 13, 2022

The race is on in eczema treatment as the biggest name faces new rivals.

Via Investor's Business Daily

FDA Approves Lilly and Incyte's OLUMIANT (baricitinib) for Hospitalized Patients with COVID-19 ↗

May 11, 2022

The U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib) for the treatment of COVID-19 in hospitalized patients.

Via Benzinga

4 Analysts Have This to Say About Incyte ↗

May 04, 2022

Analysts have provided the following ratings for Incyte (NASDAQ:INCY) within the last quarter:

Via Benzinga

Despite Q1 Earnings Miss, Incyte Shares Jump On Revised FY22 Sales Guidance ↗

May 03, 2022

Via Benzinga

Incyte: Q1 Earnings Insights ↗

May 03, 2022

Incyte (NASDAQ:INCY) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗

May 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease

May 05, 2022

From Incyte

Via Business Wire

Incyte to Present at Upcoming Investor Conference

May 04, 2022

From Incyte

Via Business Wire

MorphoSys-Incyte Partnered Minjuvi Temporarily Approved In Switzerland ↗

March 23, 2022

The

Via Benzinga

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗

May 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs

May 03, 2022

From Incyte

Via Business Wire

Global Cord Blood Enters Therapy Market Via Cellenkos Acquisition For Over $600M ↗

May 02, 2022

Global Cord Blood Corporation (NYSE: CO) will acquire Cellenkos Inc and the rights to develop and commercialize all of its existing and future products worldwide.

Via Benzinga

The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗

May 02, 2022

Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...

Via Benzinga

3 Nasdaq Stocks to Buy Now for Growth ↗

May 01, 2022

These are the best Nasdaq stocks to invest in now. INCY, ROKU and FTXL can make great investments in the rest of the year.

Via InvestorPlace

Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan

April 28, 2022

From Incyte

Via Business Wire

EMA's Advisory Committee Backs Approval Of Incyte's Capmatinib In Advanced Lung Cancer Setting ↗

April 22, 2022

Via Benzinga

Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer

April 22, 2022

From Incyte

Via Business Wire

How To Attend Incyte Q1 2022 Earnings Conference Call ↗

April 21, 2022

Incyte (NASDAQ:INCY) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Incyte (INCY) Conference Call Follow this link to access the live...

Via Benzinga

Incyte to Report First Quarter Financial Results

April 12, 2022

From Incyte

Via Business Wire

The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy ↗

April 06, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

This Favorable Sign Appears On Incyte's Chart ↗

April 05, 2022

If history is any guide, there may be good fortune ahead for shares of Incyte (NASDAQ:INCY). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the...

Via Benzinga

Incyte's Ruxolitinib Shows Further Improvement In Facial, Total Body Re-pigmentation At 52 Weeks In Skin Disorder ↗

March 28, 2022

Incyte Corporation (NASDAQ: INCY)

Via Benzinga

Incyte-Lilly's Olumiant Continue To Show Improved Scalp, Eyebrows, Eyelash Hair Regrowth At 52 Weeks ↗

March 28, 2022

At the American Academy of Dermatology Annual Meeting, Eli Lilly And Co (NYSE: LLY) and Incyte Corp (NASDAQ: INCY)

Via Benzinga

Incyte Announces 52-Week Data From the Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo

March 26, 2022

From Incyte

Via Business Wire

Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease

March 25, 2022

From Incyte

Via Business Wire

The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale ↗

March 23, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Incyte Announces Multiple Abstracts from its Dermatology Portfolio have been Accepted for Presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting

March 18, 2022

From Incyte

Via Business Wire

< Previous 1 2

...

18 19 20 21 22 23 24 25 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Incyte Corporation - Common Stock (NQ:INCY)

All News about Incyte Corporation - Common Stock

Starting at $3.75/week.

Subscribe Today